PMID- 16585865
OWN - NLM
STAT- MEDLINE
DCOM- 20060425
LR  - 20121115
IS  - 0023-852X (Print)
IS  - 0023-852X (Linking)
VI  - 116
IP  - 4
DP  - 2006 Apr
TI  - Growth suppression of human laryngeal squamous cell carcinoma by 
      adenovirus-mediated tissue factor pathway inhibitor gene 2.
PG  - 596-601
AB  - OBJECTIVE: The purpose of this study was to explore the inhibiting role of 
      adenoviral-mediated (Ad)-tissue factor pathway inhibitor (TFPI)-2 gene in the 
      growth of laryngeal squamous cell carcinoma (LSCC). STUDY DESIGN: The nude mice 
      bearing LSCC were prepared by intracutaneous injection of Hep-2 cell. Gene 
      therapy was performed by injecting adenoviruses carrying TFPI-2 gene around 
      tumors in the animal model. METHODS: Eighteen nude mice bearing Hep-2 cell tumor 
      were randomly separated into the treated group and control group. The former were 
      injected with recombinant adenovirus Ad-TFPI-2 around the tumor, and the later 
      were injected with equivalent Ad-LacZ. After treatment, differences of tumor 
      weight, volume, and ultrastructure of tumor cells between these two groups were 
      observed by measuring and using transmission electron microscope. Apoptosis in 
      Hep-2 xenotransplants was detected using the terminal deoxy-transferase-mediated 
      dUTP nick end labeling. In addition, the expressions of TFPI-2 protein and 
      proliferating cell nuclear antigen (PCNA) in tumor tissues were detected using 
      Western blot and immunohistochemistry, respectively. RESULTS: The average weight 
      and volume of tumor in the treated group were significantly lower than that in 
      the control group (P < .01). The PCNA index was obviously lower in the tumors 
      treated group than that in the control group (P < .01). In addition, cell 
      apoptosis was observed in xenotransplants of the treated group but not in the 
      control group. CONCLUSION: Peritumor injection of Ad-TFPI-2 can inhibit growth of 
      LSCC in nude mice model, and TFPI-2 might be a desirable gene for gene therapy in 
      LSCC.
FAU - Sun, Yanan
AU  - Sun Y
AD  - Department of Otorhinolaryngology--Head and Neck Surgery, The Second Affiliated 
      Hospital, Harbin Medical University, Harbin, People's Republic of China.
FAU - Xie, Minqiang
AU  - Xie M
FAU - Liu, Ming
AU  - Liu M
FAU - Jin, Dejun
AU  - Jin D
FAU - Li, Peng
AU  - Li P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (Glycoproteins)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 0 (tissue-factor-pathway inhibitor 2)
RN  - EC 3.4.21.21 (Factor VIIa)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Animals
MH  - Apoptosis
MH  - Blotting, Western
MH  - Carcinoma, Squamous Cell/metabolism/*pathology/therapy
MH  - Cell Line, Tumor
MH  - Factor VIIa/antagonists & inhibitors
MH  - Genetic Therapy/*methods
MH  - Genetic Vectors
MH  - Glycoproteins/biosynthesis/genetics/*therapeutic use
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/metabolism/*pathology/therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Microscopy, Electron, Transmission
MH  - Proliferating Cell Nuclear Antigen/metabolism
MH  - Serine Proteinase Inhibitors/genetics/*therapeutic use
EDAT- 2006/04/06 09:00
MHDA- 2006/04/28 09:00
CRDT- 2006/04/06 09:00
PHST- 2006/04/06 09:00 [pubmed]
PHST- 2006/04/28 09:00 [medline]
PHST- 2006/04/06 09:00 [entrez]
AID - 00005537-200604000-00016 [pii]
AID - 10.1097/01.mlg.0000205589.84020.d2 [doi]
PST - ppublish
SO  - Laryngoscope. 2006 Apr;116(4):596-601. doi: 10.1097/01.mlg.0000205589.84020.d2.